AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

A research team led by Professor Lee Kun-hee at Gangdong Kyunghee University Hospital has announced new evaluation criteria ...

A new study published in the Ear, Nose and Throat Journal found that the severity of chronic rhinosinusitis with nasal ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

This includes $2 billion of new investment creating more than a ... trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala ...

Whether you want passive income or not, dividend-paying stocks tend to outperform their non-dividend-paying cousins.

A trio of relatives in New Jersey defrauded the state’s Medicaid program out of millions of dollars while neglecting patient care, the state comptroller found. By Shayla Colon A New York City ...

GSK said the US Food and Drug Administration has agreed to look at data from its MATINEE study to support the regulatory review process to obtain a new use of its Nucala drug as an add-on maintenance ...

British drug maker GSK plc (GSK, GSK.L) announced Monday that the U.S. Food and Drug Administration has accepted for review, data ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...